Summaryobjectives In human African trypanosomiasis (HAT, sleeping sickness), staging of disease and treatment follow-up relies on white cell count in the cerebrospinal fluid (CSF). As B lymphocytes (CD19 positive cells) are not found in the CSF of healthy individuals but occur in neurological disorders such as multiple sclerosis, B lymphocyte count may be useful for field diagnosis ⁄ staging and therapeutic followup in HAT.methods Seventy-one HAT patients were diagnosed and 50 were followed-up 6-24 months after treatment. White cell counts were used for conventional staging (stage 1, £5 cells ⁄ ll CSF, n = 42; stage 2, ‡20 cells ⁄ ll, n = 16) and intermediate stage (6-19 cells ⁄ ll, n = 13). Slides containing 1 ll of CSF mixed with Dynabeads Ò CD19 pan B were examined microscopically to detect B cell rosettes (bound to at least four beads).results Stage 1 patients exhibited zero (n = 37) or one CSF rosette ⁄ ll (n = 5), contrary to most stage 2 patients (14 ⁄ 16: ‡2 rosettes ⁄ ll). Intermediate stage patients expressed 0 (n = 9), 1 (n = 3) or 2 (n = 1) rosettes ⁄ ll of CSF. During follow-up, rosette counts correlated with white cell count staging but were much easier to read.conclusion B cell rosettes being easily detected in the CSF in field conditions may be proposed to replace white cell count for defining HAT stages 1 and 2 and limit uncertainty in treatment decision in patients with intermediate stage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.